Shire Plc. (SHPGF) - OTCPK - Current
  • Jun. 25, 2012, 9:29 AM

    Shares of drug maker Shire (SHPGY, SHPGF.PK) -13% in London trading on news the FDA approved a generic version of its attention-deficit and hyperactivity drug Adderall XR. Watson Pharma's (WPI) newly acquired Actavis division obtained an abbreviated new-drug application for the generic. SHPGY -12.2%, WPU +1.9% premarket.

    | Jun. 25, 2012, 9:29 AM
  • Jun. 12, 2012, 9:07 AM

    BioMarin Pharmaceutical (BMRN) +4.8% premarket on rumors that Glaxo (GSK) is in advanced discussions toward a $5B buyout of BMRN. Last week, Shire (SHPGY, SHPGF.PK) also was said to be stalking the company. Glaxo is already engaged in a hostile $2.6B takeover bid for Human Genome Sciences.

    | Jun. 12, 2012, 9:07 AM
  • Jun. 22, 2011, 9:52 AM

    Achillion Pharmaceuticals (ACHN +11.5%) jumps after pricing its secondary offering at $5.90, a 1.8% discount to yesterday's close. The company plans to use the $52M it raised to bring its new line of hepatitis-c drugs to market.

    | Jun. 22, 2011, 9:52 AM
Company Description
Sector: Healthcare
Industry: Drug Manufacturers - Major
Country: Ireland